Zobrazeno 1 - 10
of 840
pro vyhledávání: '"RC254-282"'
Autor:
Emil Joseph Vergara, Andy Cano Tran, Matthew J. Paul, Thomas Harrison, Andrea Cooper, Rajko Reljic
Publikováno v:
npj Vaccines, Vol 9, Iss 1, Pp 1-13 (2024)
Abstract The Mycobacterial growth inhibition assay (MGIA) is an ex-vivo assay used to measure the overall functional immune response elicited by infection or vaccination. In tuberculosis (TB) vaccine development, MGIA is a potentially important tool
Externí odkaz:
https://doaj.org/article/9b3bb21202974b06bf1422780d222276
Autor:
Borimas Hanboonkunupakarn, Mavuto Mukaka, Podjanee Jittamala, Kittiyod Poovorawan, Pongphaya Pongsuwan, Lisa Stockdale, Samuel Provstgaard-Morys, Kesinee Chotivanich, Joel Tarning, Richard M. Hoglund, Natenapa Chimjinda, Katie Ewer, Fernando Ramos-Lopez, Nicholas P. J. Day, Arjen M. Dondorp, Adrian V. Hill, Nicholas J. White, Lorenz von Seidlein, Sasithon Pukrittayakamee
Publikováno v:
npj Vaccines, Vol 9, Iss 1, Pp 1-8 (2024)
Abstract In preparation for mass vaccinations with R21/Matrix-M™ combined with mass administrations of dihydroartemisinin, piperaquine, and a single low dose primaquine we assessed the tolerability, safety, and potential interactions of this combin
Externí odkaz:
https://doaj.org/article/4be06bd127144f78b5cc122df3526075
Autor:
Wesley A. Bland, Dipanwita Mitra, Shana Owens, Kyle McEvoy, Chad H. Hogan, Luciarita Boccuzzi, Varvara Kirillov, Thomas J. Meyer, Camille Khairallah, Brian S. Sheridan, J. Craig Forrest, Laurie T. Krug
Publikováno v:
npj Vaccines, Vol 9, Iss 1, Pp 1-17 (2024)
Abstract Gammaherpesviruses are oncogenic viruses that establish lifelong infections and are significant causes of morbidity and mortality. Vaccine strategies to limit gammaherpesvirus infection and disease are in development, but there are no FDA-ap
Externí odkaz:
https://doaj.org/article/a63769ba599a42ebaa127181f2f65fb4
Autor:
Kristina R. Edwards, Harman Malhi, Karina Schmidt, Amelia R. Davis, Leah J. Homad, Nikole L. Warner, Crystal B. Chhan, Samuel C. Scharffenberger, Karen Gaffney, Troy Hinkley, Nicole B. Potchen, Jing Yang Wang, Jason Price, M. Juliana McElrath, James Olson, Neil P. King, Jennifer M. Lund, Zoe Moodie, Jesse H. Erasmus, Andrew T. McGuire
Publikováno v:
npj Vaccines, Vol 9, Iss 1, Pp 1-16 (2024)
Abstract Epstein-Barr virus (EBV) is associated with several malignancies, neurodegenerative disorders and is the causative agent of infectious mononucleosis. A vaccine that prevents EBV-driven morbidity and mortality remains an unmet need. EBV is or
Externí odkaz:
https://doaj.org/article/fab2a8de7ed045b19c19552e4e00f12e
Autor:
Cameron Bissett, Sandra Belij-Rammerstorfer, Marta Ulaszewska, Holly Smith, Reshma Kailath, Susan Morris, Claire Powers, Sarah Sebastian, Hannah R. Sharpe, Elizabeth R. Allen, Ziyin Wang, Robert F. Cunliffe, Hadijatou J. Sallah, Alexandra J. Spencer, Sarah Gilbert, John S. Tregoning, Teresa Lambe
Publikováno v:
npj Vaccines, Vol 9, Iss 1, Pp 1-14 (2024)
Abstract Although licensed vaccines against influenza virus have been successful in reducing pathogen-mediated disease, they have been less effective at preventing viral infection of the airways and current seasonal updates to influenza vaccines do n
Externí odkaz:
https://doaj.org/article/07987297f82141069454fe091bb1a243
Autor:
Hadas Bar-Joseph, Yael Raz, Anat Eldar-Boock, Nadav Michaan, Yoel Angel, Esther Saiag, Luba Nemerovsky, Ido Ben-Ami, Ruth Shalgi, Dan Grisaru
Publikováno v:
npj Vaccines, Vol 9, Iss 1, Pp 1-9 (2024)
Abstract Following administration of the SARS-CoV-2 vaccine, many women worldwide reported short-term menstrual irregularities. Although menstrual bleeding, “the fifth vital sign”, is experienced by more than 300 million people on any given day w
Externí odkaz:
https://doaj.org/article/d0db445cc1aa492486702f2d2e5352d4
Publikováno v:
npj Vaccines, Vol 9, Iss 1, Pp 1-8 (2024)
Abstract Following the start of the COVID-19 vaccination campaign, the adverse events of myocarditis and pericarditis were linked mainly to mRNA COVID-19 vaccines by the regulatory authorities worldwide. COVID-19 vaccines have been administered to se
Externí odkaz:
https://doaj.org/article/441fcc7f550349169b1d22b57ac5e1a2
Autor:
Xueer Zhao, Yueru Zhang, Oscar Trejo-Cerro, Ecem Kaplan, Zhe Li, Femke Albertsboer, Neyla El Hammiri, Filipe Colaço Mariz, Lawrence Banks, Simone Ottonello, Martin Müller
Publikováno v:
npj Vaccines, Vol 9, Iss 1, Pp 1-12 (2024)
Abstract Persistent infection with high-risk human papillomavirus (HPV) is widely recognized as the primary cause of cervical and other malignant cancers. There are six licensed prophylactic vaccines available against HPV, but none of them shows any
Externí odkaz:
https://doaj.org/article/9217cc3d10dd4b0fa85b0fbc8c538da5
Evaluation of mRNA-LNP and adjuvanted protein SARS-CoV-2 vaccines in a maternal antibody mouse model
Autor:
Ross N. England, Elizabeth M. Drapeau, Mohamad-Gabriel Alameh, Reihaneh Hosseinzadeh, Drew Weissman, Scott E. Hensley
Publikováno v:
npj Vaccines, Vol 9, Iss 1, Pp 1-8 (2024)
Abstract Maternal antibodies (matAbs) protect against a myriad of pathogens early in life; however, these antibodies can also inhibit de novo immune responses against some vaccine platforms. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2
Externí odkaz:
https://doaj.org/article/ce31953d47bc4fc28564989d3cbd2e47
Autor:
Himanshu Singh Saroha, Swati Bhat, Liza Das, Pinaki Dutta, Michael F. Holick, Naresh Sachdeva, Raman Kumar Marwaha
Publikováno v:
npj Vaccines, Vol 9, Iss 1, Pp 1-12 (2024)
Abstract The ChAdOx1 nCoV-19 (COVISHIELD) vaccine has emerged as a pivotal tool in the global fight against the COVID-19 pandemic. In our previous study eligible subjects were supplemented with calcifediol, a direct precursor to the biologically acti
Externí odkaz:
https://doaj.org/article/19176f90ff2345e6b1aaf47c4017dbc1